The study achieved its primary objective of superiority of anxiolytic effects ... GAD. EFFEXOR® is currently approved in Japan for the indication of major depressive disorder in adults.

(NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR ® (venlafaxine) in adults ...

(RTTNews) - Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults with ... of anxiolytic effects of venlafaxine ...

in Japan evaluating the safety and efficacy of EFFEXOR ® (venlafaxine) in adults with generalized anxiety disorder (GAD). The study achieved its primary objective of superiority of anxiolytic ...

Treatment with once-daily EFFEXOR ... venlafaxine) in adults with generalized anxiety disorder (GAD). The study achieved its primary objective of superiority of anxiolytic effects of venlafaxine ...

(NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine) in ...

Strattera (atomoxetine) is a prescription drug used to treat attention deficit hyperactivity disorder (ADHD) in adults and some children. Strattera can cause side effects that range from mild to ...